You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY21 is not expected to be complete until September, 2022.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

  1. Nonlinear Computation Tool to Chart Trajectories of Bipolar Disorder

    SBC: Biomedical Development Corporation            Topic: 103

    DESCRIPTION provided by applicant Bipolar disorder BD is a complex chronic illness characterized by recurrent often dramatic mood changes Self management of BD is an important component of treatment but is likewise complex and can be fraught with difficulties including misunderstanding of the condition and a lack of self awareness Combined with the nationwide shortage of mental healthcare ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  2. Development of An Integrated High Throughput Imaging and Image Analysis Platform for Muscle

    SBC: CytoInformatics LLC            Topic: NIA

    DESCRIPTION provided by applicant There is growing awareness that weakness of muscle is a significant biomedical health issue associated with many different chronic diseases and aging There are a variety of different diseases that affect muscle including muscular dystrophy fibromyalgia cerebral palsy amyotrophic lateral sclerosis and myasthenia gravis each of which carries its own uniqu ...

    STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection

    SBC: L2 Diagnostics, LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial to the pathogenesis of P aeruginosa in vivo but has not yet been exploited for antimicrobial drug discovery There is a clear need for new treatments to combat P aeruginosa infections Antibiotic re ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Small molecule inhibitors targeting oncogenic drivers of hepatocellular carcinoma

    SBC: L2 Diagnostics, LLC            Topic: 102

    DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. A Method to Increase Buprenorphine Treatment Capacity and Effectiveness

    SBC: CBT4CBT, LLC            Topic: R42

    The goal of this fast track STTR proposal is to expand buprenorphine maintenance therapy for opioid dependent patients Over million people in the US are addicted to opiates Providing effective agonist therapy methadone or buprenorphine coupled with behavioral counseling greatly improves outcomes reduces morbidity and reduces societal costs Methadone maintenance treatment has been limit ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  6. Developing a novel adjuvant system for therapeutic vaccines against lung cancer

    SBC: FasCure Therapeutics LLC            Topic: 102

    DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  7. Improving the therapeutic efficacy of a lead vaccine against plague using a novel adjuvant system

    SBC: FasCure Therapeutics LLC            Topic: NIAID

    DESCRIPTION provided by applicant FasCure Therapeutics focuses on the development of adjuvant systems to generate prophylactic and therapeutic immune responses The major objective of this Phase STTR proposal is to reformulate a lead plague subunit vaccine with a novel adjuvant system to improve its protective efficacy Yersinia pestis is the causative agent of bubonic and pneumonic plague ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Measuring toxicant effects on cellular function in a microarray format

    SBC: CIENCIA INC            Topic: NIEHS

    DESCRIPTION provided by applicant The EPA maintains a Toxics Release Inventory of over toxic chemicals that are disposed or released from more than industrial sites in the United States The Department of Health and Human Services and USDA maintain a list of over select agents and toxins that pose a severe risk to both human animal and plant health These compounds represent only ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Development of an Osteoinductive Spinal Fusion Implant for Enhanced Fusion Rates

    SBC: Evoke Medical, LLC            Topic: NIAMS

    DESCRIPTION provided by applicant The objective of this Phase I STTR research is to develop and test osteoinductive lumbar spinal fusion implant prototypes made using materials technology developments discovered by the PI at the University of Kansas In preliminary work lower impedance piezoelectric composite materials that generate power for direct current DC electrical stimulation applica ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Engineering a phosphotyrosyl-tRNA Synthetase

    SBC: AXIOMX INC            Topic: 300

    DESCRIPTION provided by applicant Although tyrosine phosphorylation is an important controlling element in cell signaling no tRNA suppressor for phosphotyrosine pTyr incorporation has yet been made We propose to use directed molecular evolution of several aminoacyl tRNA synthetases aaRSs to identify mutations that enable binding of pTyr to the aaRS Specifically ATP molecules will be att ...

    STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government